Natera, Inc.(NTRA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NTRA Natera, Inc.

盘后交易 10-27 18:10:37 EDT

192.22

-0.29

-0.15%

盘后192.54

+0.32+0.17%

17:47 EDT

最高195.44	最低189.38	成交量110.88万
今开194.72	昨收192.51	日振幅3.15%
总市值263.82亿	流通市值255.37亿	总股本1.37亿
成交额2.13亿	换手率0.83%	流通股本1.33亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NTRA","market":"US","secType":"STK","nameCN":"Natera, Inc.","latestPrice":192.22,"timestamp":1761595200000,"preClose":192.51,"halted":0,"volume":1108838,"hourTrading":{"tag":"盘后","latestPrice":192.54,"preClose":192.22,"latestTime":"17:47 EDT","volume":15139,"amount":2910018.42861,"timestamp":1761601655120},"delay":0,"floatShares":132854066,"shares":137248106,"eps":-1.924044,"marketStatus":"盘后交易","change":-0.29,"latestTime":"10-27 18:10:37 EDT","open":194.72,"high":195.435,"low":189.38,"amount":213257822.769,"amplitude":0.031453,"askPrice":192.54,"askSize":5,"bidPrice":185,"bidSize":7,"shortable":3,"etf":0,"ttmEps":-1.924044,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1761609600000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1435809600000,"exchange":"NASDAQ","adjPreClose":192.51,"preHourTrading":{"tag":"盘前","latestPrice":194.86,"preClose":192.51,"latestTime":"09:29 EDT","volume":446,"amount":86837.67626,"timestamp":1761571799999},"postHourTrading":{"tag":"盘后","latestPrice":192.54,"preClose":192.22,"latestTime":"17:47 EDT","volume":15139,"amount":2910018.42861,"timestamp":1761601655120},"volumeRatio":0.943409,"impliedVol":0.5644,"impliedVolPercentile":0.56},"requestUrl":"/m/hq/s/NTRA","defaultTab":"news","newsList":[{"id":"1174935558","title":"Natera, Inc.: Imvigor011试验取得成功，膀胱癌患者整体生存率提高41%","url":"https://stock-news.laohu8.com/highlight/detail?id=1174935558","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174935558?lang=zh_cn&edition=full","pubTime":"2025-10-20 13:07","pubTimestamp":1760936830,"startTime":"0","endTime":"0","summary":"Natera, Inc.: Imvigor011试验取得成功，膀胱癌患者整体生存率提高41%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","LU2065170008.USD","LU0345770993.USD","LU1988902786.USD","LU0345770308.USD","LU0963586101.USD","LU2264538146.SGD","NTRA","LU1064131342.USD","LU2065731478.USD","LU2324357040.USD","BK4139","LU0012050646.USD","LU2065171311.SGD","LU2065169927.USD","LU0106261612.USD","LU0053671581.USD"],"gpt_icon":0},{"id":"1193796018","title":"Natera：额外口头报告包括Sunrise-4试验结果、结直肠癌Intercept试验以及Natera早期癌症检测项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1193796018","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193796018?lang=zh_cn&edition=full","pubTime":"2025-10-13 06:14","pubTimestamp":1760307254,"startTime":"0","endTime":"0","summary":"Natera：额外口头报告包括Sunrise-4试验结果、结直肠癌Intercept试验以及Natera早期癌症检测项目","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131342.USD","LU2264538146.SGD","LU2065169927.USD","LU2065171402.SGD","LU2065731478.USD","LU2324357040.USD","NTRA","LU2065171311.SGD","LU0963586101.USD","BK4139","LU0345770993.USD","LU0053671581.USD","LU0106261612.USD","LU0012050646.USD","LU1988902786.USD","LU2065170008.USD","LU0345770308.USD"],"gpt_icon":0},{"id":"2564134360","title":"RBC Raises Price Target on Natera to $268 From $255, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2564134360","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564134360?lang=zh_cn&edition=full","pubTime":"2025-09-03 19:25","pubTimestamp":1756898757,"startTime":"0","endTime":"0","summary":"Natera (NTRA) has an average rating of buy and mean price target of $207.35, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and r","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"加拿大皇家银行将Natera目标价从255美元上调至268美元，维持跑赢大盘评级","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NTRA"],"gpt_icon":0},{"id":"1149199189","title":"NeoGenomics专利诉讼胜利对股价构成利好 -- 市场观察","url":"https://stock-news.laohu8.com/highlight/detail?id=1149199189","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149199189?lang=zh_cn&edition=full","pubTime":"2025-08-30 01:38","pubTimestamp":1756489116,"startTime":"0","endTime":"0","summary":"NeoGenomics在与Natera的专利侵权诉讼中获得简易判决胜利，消除了股票面临的部分诉讼阻力，为股价提供了催化剂，Benchmark分析师Bruce Jackson在研究报告中表示。得益于这一裁决，这家癌症检测公司将能够继续在美国制造、使用、销售和推广其RaDaR ST分子残留疾病检测法。\n另一方面，Natera表示正在评估其选择，包括上诉以及通过其他专利进一步执法。NeoGenomics股价大涨24%，而Natera股价基本持平。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","LU0053671581.USD","LU0345770308.USD","LU0106261612.USD","LU1988902786.USD","BK4196","BK4139","LU2065169927.USD","LU2065171311.SGD","BK4121","LU1064131342.USD","LU2264538146.SGD","LU2065170008.USD","LU2065731478.USD","LU0963586101.USD","LU0345770993.USD","LU2324357040.USD","LU0012050646.USD","NEO","NTRA"],"gpt_icon":0},{"id":"2557527651","title":"RBC Raises Price Target on Natera to $255 From $251, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2557527651","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557527651?lang=zh_cn&edition=full","pubTime":"2025-08-08 21:15","pubTimestamp":1754658931,"startTime":"0","endTime":"0","summary":"Natera (NTRA) has an average rating of buy and mean price target of $204.70, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and r","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"加拿大皇家银行将Natera目标价从251美元上调至255美元，维持跑赢大盘评级","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NTRA"],"gpt_icon":0},{"id":"1186073530","title":"异动解读 | Natera股价盘前大涨13.43%，Q2业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1186073530","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186073530?lang=zh_cn&edition=full","pubTime":"2025-08-08 19:08","pubTimestamp":1754651320,"startTime":"0","endTime":"0","summary":"8月8日周五盘前，生物技术公司Natera, Inc.股价大涨13.43%，主要受益于公司发布的2025财年第二季度强劲财报。根据Natera公布的财报，公司2025财年第二季度实现收入5.466亿美元，同比增长32.2%，远超分析师预期的4.7629亿美元。展望未来，Natera管理层上调了全年收入指引至20.2亿至21亿美元，并将毛利率指引提高至61%-64%。尽管市场渗透率仍然较低，但Natera对其在各类肿瘤检测市场的扩张机会持乐观态度，这也增强了投资者对公司长期增长前景的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NTRA"],"gpt_icon":1},{"id":"1165029792","title":"异动解读 | 业绩超预期，Natera夜盘大涨10.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=1165029792","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165029792?lang=zh_cn&edition=full","pubTime":"2025-08-08 08:23","pubTimestamp":1754612620,"startTime":"0","endTime":"0","summary":"生物技术公司Natera, Inc.在夜盘交易中股价大涨10.83%，引起投资者广泛关注。根据Natera公布的财报，公司2025财年第二季度实现收入5.47亿美元，同比增长32%，环比增长9%，超出分析师预期。Natera的业绩增长主要得益于其肿瘤检测量创下新高，以及改善的报销动态。尽管市场渗透率仍然较低，但Natera管理层对公司在各类肿瘤检测市场的扩张机会持乐观态度，这也增强了投资者对公司长期增长前景的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NTRA"],"gpt_icon":1},{"id":"1149778830","title":"Natera 2025财年Q2业绩会总结及问答精华：创新推动增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1149778830","media":"业绩会速递","labels":["earningsCall","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149778830?lang=zh_cn&edition=full","pubTime":"2025-08-08 06:52","pubTimestamp":1754607164,"startTime":"0","endTime":"0","summary":"Natera在2025财年第二季度实现了32%的收入增长，达到5.47亿美元，主要得益于肿瘤检测量的创新高和改善的报销动态。同比增长32%，环比增长9%。医生开始在不同肿瘤类型中使用Signatera，显示出广泛的市场机会。Find试验已经开始招募，预计2027年提交FDA。Natera在2025财年第二季度表现强劲，收入和毛利率均超出预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"earningsCall,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"gpt_icon":0},{"id":"2557599665","title":"Natera Q2 EPS $(0.74) Misses $(0.61) Estimate, Sales $546.600M Beat $475.451M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2557599665","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557599665?lang=zh_cn&edition=full","pubTime":"2025-08-08 04:28","pubTimestamp":1754598534,"startTime":"0","endTime":"0","summary":"Natera (NASDAQ:NTRA) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of $(0.61) by 20.52 percent. This is a 146.67 percent decrease over losses of $(0.30) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"Natera第二季度EPS$(0.74)低于$(0.61)预期，销售额5.466亿美元超出预期4.75451亿美元","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/46980922/natera-q2-eps-0-74-misses-0-61-estimate-sales-546-600m-beat-475-451m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Natera Q2 EPS $(0.74) Misses $(0.61) Estimate, Sales $546.600M Beat $475.451M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"gpt_icon":0},{"id":"2535876881","title":"Piper Sandler：维持Natera评级，由增持调整至增持评级, 目标价由205.00美元调整至210.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2535876881","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535876881?lang=zh_cn&edition=full","pubTime":"2025-05-16 00:32","pubTimestamp":1747326767,"startTime":"0","endTime":"0","summary":"Piper Sandler：维持Natera(NTRA.US)评级，由增持调整至增持评级, 目标价由205.00美元调整至210.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051600353994f8189b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NTRA"],"gpt_icon":0},{"id":"2534469197","title":"瑞银：维持Natera评级，由买入调整至买入评级, 目标价由211.00美元调整至218.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2534469197","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534469197?lang=zh_cn&edition=full","pubTime":"2025-05-10 06:01","pubTimestamp":1746828105,"startTime":"0","endTime":"0","summary":"瑞银：维持Natera(NTRA.US)评级，由买入调整至买入评级, 目标价由211.00美元调整至218.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505100605299754e55f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NTRA"],"gpt_icon":0},{"id":"2534620411","title":"Natera Q1 Net Loss Narrows, Revenue Rises; Increases Full Year Revenue Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2534620411","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534620411?lang=zh_cn&edition=full","pubTime":"2025-05-09 04:55","pubTimestamp":1746737743,"startTime":"0","endTime":"0","summary":"Natera  reported late Thursday a Q1 net loss of $0.50 per diluted share, narrowing from a loss of $0.56 a year earlier.Analysts polled by FactSet expected a loss of $0.64.Revenue for the three months ended March 31 was $501.8 million, up from $367.7 million a year earlier. Analysts expected $446.2 million.For full-year 2025, the company raised its outlook for revenue to $1.94 billion to $2.02 billion from the previously provided range of $1.87 billion to $1.95 billion. Analysts are looking for $1.92 billion.Shares of the company were up 1.5% in recent after-hours activity.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"Natera Q1净亏损收窄，营收上升；提高全年收入前景","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NTRA"],"gpt_icon":0},{"id":"2534576169","title":"Natera Q1 EPS $(0.50) Beats $(0.64) Estimate, Sales $501.83M Beat $446.27M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2534576169","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534576169?lang=zh_cn&edition=full","pubTime":"2025-05-09 04:13","pubTimestamp":1746735229,"startTime":"0","endTime":"0","summary":"Natera Q1 EPS $(0.50) Beats $(0.64) Estimate, Sales $501.83M Beat $446.27M Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"Natera第一季度每股收益(0.50)美元超出预期(0.64)美元，销售额5.0183亿美元超出预期4.4627亿美元","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45300020/natera-q1-eps-0-50-beats-0-64-estimate-sales-501-83m-beat-446-27m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.natera.com","stockEarnings":[{"period":"1week","weight":0.0596},{"period":"1month","weight":0.1745},{"period":"3month","weight":0.386},{"period":"6month","weight":0.2518},{"period":"1year","weight":0.6154},{"period":"ytd","weight":0.2161}],"compareEarnings":[{"period":"1week","weight":0.0194},{"period":"1month","weight":0.0244},{"period":"3month","weight":0.063},{"period":"6month","weight":0.2299},{"period":"1year","weight":0.1692},{"period":"ytd","weight":0.1556}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Natera, Inc.于2007年1月在特拉华州成立。该公司是一家诊断公司，拥有专有的分子和生物信息技术，该公司正在应用该技术来改变全球范围内的疾病管理。该公司的无细胞DNA（CFDNA）技术结合了新颖的分子分析方法，这些方法可以从小到单个细胞的样本中可靠地测量整个基因组中的许多信息区域，以及统计算法，这些算法结合了更广泛的科学界提供的数据，以高精度和高覆盖率识别涵盖广泛严重疾病的遗传变异。该公司的目标是使个性化基因检测和诊断成为保护健康的护理标准的一部分，并告知更早和更有针对性的干预措施，以帮助实现更长寿、更健康的生活。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.020548},{"month":2,"riseRate":0.6,"avgChangeRate":0.03105},{"month":3,"riseRate":0.5,"avgChangeRate":0.006098},{"month":4,"riseRate":0.7,"avgChangeRate":0.036291},{"month":5,"riseRate":0.8,"avgChangeRate":0.098678},{"month":6,"riseRate":0.8,"avgChangeRate":0.118334},{"month":7,"riseRate":0.4,"avgChangeRate":0.001285},{"month":8,"riseRate":0.818182,"avgChangeRate":0.153134},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.04947},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.041867},{"month":11,"riseRate":0.5,"avgChangeRate":0.090493},{"month":12,"riseRate":0.4,"avgChangeRate":0.003242}],"exchange":"NASDAQ","name":"Natera, Inc.","nameEN":"Natera"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.4","shortVersion":"4.35.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Natera, Inc.(NTRA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Natera, Inc.(NTRA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Natera, Inc.,NTRA,Natera, Inc.股票,Natera, Inc.股票老虎,Natera, Inc.股票老虎国际,Natera, Inc.行情,Natera, Inc.股票行情,Natera, Inc.股价,Natera, Inc.股市,Natera, Inc.股票价格,Natera, Inc.股票交易,Natera, Inc.股票购买,Natera, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Natera, Inc.(NTRA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Natera, Inc.(NTRA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}